Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- Exploratory Study of PENNSAID Gel to Treat Symptoms of Knee Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of Exploratory Study of PENNSAID Gel to Treat Symptoms of Knee Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant: Complete Statistical AnalysisIndependent statistical analysis of Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD): Complete Statistical AnalysisIndependent statistical analysis of Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Exploratory Subjective Sleep Study of a Prototype Nasal Dilator: Complete Statistical AnalysisIndependent statistical analysis of Exploratory Subjective Sleep Study of a Prototype Nasal Dilator: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01122849).
- Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years: Complete Statistical AnalysisIndependent statistical analysis of Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- EXPLOREIndependent statistical analysis of EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- EXPLORER PET/CT: Evaluation of Healthy Individuals From Racial/Ethnic Minority Populations: Complete Statistical AnalysisIndependent statistical analysis of EXPLORER PET/CT: Evaluation of Healthy Individuals From Racial/Ethnic Minority Populations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04812080).
- explorer™5Independent statistical analysis of A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors: primary endpoint results, effect estimate with confidence interval, sample-size…
- Exploring Life Experience and Lifestyle Intervention Program Among Patients With CKD: Complete Statistical AnalysisIndependent statistical analysis of Exploring Life Experience and Lifestyle Intervention Program Among Patients With CKD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Exploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution: Complete Statistical AnalysisIndependent statistical analysis of Exploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Exploring the Effects of Corticosteroids on the Human Hippocampus: Complete Statistical AnalysisIndependent statistical analysis of Exploring the Effects of Corticosteroids on the Human Hippocampus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03896659).
- Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures: Complete Statistical AnalysisIndependent statistical analysis of Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures: primary endpoint results, effect estimate with…
- Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration: Complete Statistical AnalysisIndependent statistical analysis of Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01737944).
- Exposure to Gun Violence in Video Games Increases Interest in Real Guns: Complete Statistical AnalysisIndependent statistical analysis of Exposure to Gun Violence in Video Games Increases Interest in Real Guns: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Exposure With Acceptance-Based Versus Habituation-Based Rationale for Public Speaking Anxiety: Complete Statistical AnalysisIndependent statistical analysis of Exposure With Acceptance-Based Versus Habituation-Based Rationale for Public Speaking Anxiety: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00842946).
- EXT-HFIndependent statistical analysis of Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- EXTAXIndependent statistical analysis of Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size…
- EXTENDIndependent statistical analysis of Evaluation of Xiaflex: Trial of Effectivenss iN Dupuytren's: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02725528).
- EXTENDIndependent statistical analysis of Exercise Effects on Brain Health and Learning From Minutes to Months: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ExtenDIndependent statistical analysis of Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery: primary endpoint results, effect estimate with confidence interval, sample-size…
- Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Extended Dosing With Eltrombopag for Severe Aplastic Anemia: Complete Statistical AnalysisIndependent statistical analysis of Extended Dosing With Eltrombopag for Severe Aplastic Anemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01891994).
- Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation: Complete Statistical AnalysisIndependent statistical analysis of Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02720536).
- Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069): Complete Statistical AnalysisIndependent statistical analysis of Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00485758).
- Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder: Complete Statistical AnalysisIndependent statistical analysis of Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users: Complete Statistical AnalysisIndependent statistical analysis of Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail: Complete Statistical AnalysisIndependent statistical analysis of Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01180647).
- Extending taVNS Paired With Infant CIMT Into a Home-Based Setting: Complete Statistical AnalysisIndependent statistical analysis of Extending taVNS Paired With Infant CIMT Into a Home-Based Setting: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05857527).
- Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898): Complete Statistical AnalysisIndependent statistical analysis of Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults: Complete Statistical AnalysisIndependent statistical analysis of Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Extension Study of IMO-8400 in Patients With Waldenström’s Macroglobulinemia Who Completed Study 8400-401: Complete Statistical AnalysisIndependent statistical analysis of Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03121586).
- Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study: Complete Statistical AnalysisIndependent statistical analysis of Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study: primary endpoint results, effect estimate with confidence interval, sample-size…
- Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia: Complete Statistical AnalysisIndependent statistical analysis of Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD (EU): Complete Statistical AnalysisIndependent statistical analysis of Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD (EU): primary endpoint results, effect estimate with confidence interval, sample-size…
- Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.: Complete Statistical AnalysisIndependent statistical analysis of Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.: primary endpoint results, effect estimate with confidence interval,…
- Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis: Complete Statistical AnalysisIndependent statistical analysis of Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3): Complete Statistical AnalysisIndependent statistical analysis of Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3): primary endpoint…
- Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.: Complete Statistical AnalysisIndependent statistical analysis of Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size…
- External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- External Trigeminal Nerve Stimulation for Epilepsy: Complete Statistical AnalysisIndependent statistical analysis of External Trigeminal Nerve Stimulation for Epilepsy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01159431).
- eXtRaIndependent statistical analysis of Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia: primary endpoint results, effect estimate with confidence interval,…
- EXTRAIndependent statistical analysis of A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA): primary endpoint results,…
- Extracorporeal Membrane Oxygenation (ECMO) in Non-intubated Patients With Acute Respiratory Distress Syndrome (ARDS): Complete Statistical AnalysisIndependent statistical analysis of Extracorporeal Membrane Oxygenation (ECMO) in Non-intubated Patients With Acute Respiratory Distress Syndrome (ARDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD): Complete Statistical AnalysisIndependent statistical analysis of Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Eye MovementIndependent statistical analysis of The Effect of Sedation on Eye Movements: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00646646).